Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewC 021 dihydrochloride is a potent CCR4 chemokine receptor antagonist (IC50 values are 0.14 and 0.039 μM for inhibition of chemotaxis in human and mouse respectively).
C 021 dihydrochloride is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. 了解 Tocris 化合物库的更多信息。
分子量 | 540.57 |
公式 | C27H41N5O2.2HCl |
储存 | Desiccate at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 1784252-84-1 |
PubChem ID | 56972238 |
InChI Key | GKJKNYQUFAPLOQ-UHFFFAOYSA-N |
Smiles | COC1=C(OC)C=C(N=C(N4CCC(N5CCCCC5)CC4)N=C2NC3CCCCCC3)C2=C1.Cl.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 26.96 | 50 | |
DMSO | 53.93 | 100 |
以下数据基于产品分子量 540.57。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.85 mL | 9.25 mL | 18.5 mL |
5 mM | 0.37 mL | 1.85 mL | 3.7 mL |
10 mM | 0.18 mL | 0.92 mL | 1.85 mL |
50 mM | 0.04 mL | 0.18 mL | 0.37 mL |
参考文献是支持产品生物活性的出版物。
Yokoyama et al (2009) Potent and orally bioavailable CCR4 antagonists: synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg.Med.Chem. 17 64 PMID: 19081254
If you know of a relevant reference for C 021 dihydrochloride, please let us know.
关键词: C 021 dihydrochloride, C 021 dihydrochloride supplier, C021, dihydrochloride, potent, CCR4, chemokines, receptors, antagonists, Chemokine, CC, Receptors, 3581, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 C 021 dihydrochloride 的部分引用包括:
Rasheed et al (2018) CCL17/TARC and CCR4 expression in Merkel cell carcinoma. Oncotarget 9 31432 PMID: 30140381
Kwon et al (2015) CCL2 Mediates Neuron-Macrophage Interactions to Drive Proregenerative Macrophage Activation Following Preconditioning Injury. J Neurosci 35 15934 PMID: 26631474
McMillin et al (2014) Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation 11 121 PMID: 25012628
Lei et al (2021) Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice. J Neuroinflammation 18 62 PMID: 33648537
Palchevskiy et al (2019) CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection. JCI Insight 5 PMID: 31085832
Lei et al (2020) Recombinant CCL17 Enhances Hematoma Resolution and Activation of CCR4/ERK/Nrf2/CD163 Signaling Pathway After Intracerebral Hemorrhage in Mice. Neurotherapeutics 17 1940-1953 PMID: 32783091
He et al (2018) Circadian Expression of Migratory Factors Establishes Lineage-Specific Signatures that Guide the Homing of Leukocyte Subsets to Tissues. Immunity 49 1175 PMID: 30527911
您是否知道使用了 Tocris C 021 dihydrochloride 的优秀论文? 请告知我们.
平均评分: 1 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
I used it both in vivo and in vitro. In vitro, I was unable to find any impact in chemotaxis towards CCL17
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.